Operations: Mensch und Maschine Software SE generates revenue primarily from its M+M Software segment (€107.71 million) and M+M Digitization segment (€216.19 million). The company's net profit margin is a key financial metric to consider.

Mensch und Maschine (MUM) has shown solid performance with a debt to equity ratio dropping from 42.8% to 15.5% over five years, and earnings growing by 7.6% in the past year, outpacing the software industry’s -4.4%. Trading at nearly 40% below its estimated fair value, MUM's interest payments are well covered by EBIT (247x). Recent results show Q2 sales of €75.1 million and net income of €7.34 million, indicating steady growth and profitability.

• Navigate through the intricacies of Mensch und Maschine Software with our comprehensive health report here.

• Assess Mensch und Maschine Software's past performance with our detailed historical performance reports.

RH?N-KLINIKUM

Simply Wall St Value Rating: ★★★★★☆

Overview: RH?N-KLINIKUM Aktiengesellschaft, along with its subsidiaries, provides in-patient, semi-patient, and outpatient healthcare services in Germany and has a market cap of approximately €809.96 million.

Operations: RH?N-KLINIKUM generates revenue primarily from acute hospitals (€1.45 billion), medical care centres (€23.90 million), and rehabilitation hospitals (€34.70 million).

RH?N-KLINIKUM, a notable player in the healthcare sector, reported second-quarter sales of €392.69 million and net income of €9.01 million. Over the past year, earnings grew by 81.6%, surpassing the industry's 30.9% growth rate. The company's debt-to-equity ratio increased to 11.1% over five years from 8.7%. With a price-to-earnings ratio of 17.4x below the industry average and positive free cash flow, RH?N-KLINIKUM appears undervalued yet promising within its niche market segment.

• Take a closer look at RH?N-KLINIKUM's potential here in our health report.

• Explore historical data to track RH?N-KLINIKUM's performance over time in our Past section.

Summing It All Up

• Gain an insight into the universe of 53 German Undiscovered Gems With Strong Fundamentals by clicking here.

• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include XTRA:M12 XTRA:MUM and XTRA:RHK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]